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A B S T R A C T
Slurry-based Letrozole (LTZ)-loaded proniosomes were designed using sucrose or sorbitol as carriers and various
ratios of cholesterol (CH) and Tween 80 (T80) as lipid composition. Proniosomes were hydrated and probe-
sonicated to generate nano-vesicles. The proniosome powders were characterized in terms of morphology using
scanning electron microscopy, and drug crystallinity using differential scanning calorimetry (DSC) and X-ray
diffraction (XRD). The niosomes generated from proniosomes were characterized and compared to conventional
niosomes, in terms of size, zeta potential, drug entrapment, storage stability, and drug release. All formulations
had size measurements in the range of 100–194 nm, polydispersity index (PDI) values below 0.3, and zeta
potential values below – 23 mV. Drug entrapment was the highest for niosomes generated from sucrose-based
proniosomes (CH:T80; 1:1), reaching 74% compared to less than 50% for conventional niosomes. Storage for
3 months at 4 °C resulted in minor drug leakage whilst most drug was leaked from vesicles stored at room
temperature. DSC and XRD studies showed that LTZ was converted into its amorphous form upon incorporation
into proniosomes. Drug release exhibited a biphasic pattern, being fast at the first 24 h (up to 65% released)
followed by a very slow release phase for a duration of one month, releasing at least 95%. The release profile of
niosomes fits best with the Higuchi model. Overall, in this study, a facile approach to generating niosomes
incorporating LTZ using a slurry-based proniosome technology was demonstrated. The niosomes provided high
drug entrapment and controlled biphasic release over one month.
1. Introduction
Breast cancer is a leading global cause of cancer-related mortality in
women [1,2] and is becoming increasingly common amongst female
patients below 40 years old [3,4]. In the Gulf Cooperation Council
(GCC) countries (the region where this research paper has been origi-
nated), breast cancer represents about 23% of all female cancer cases
between 1998 and 2007, and the percentage is expected to increase in
2020 [5].
Amongst many anticancer agents, letrozole (LTZ), a third-genera-
tion selective non-steroidal aromatase inhibitor, has obtained FDA ap-
proval as an adjuvant treatment of estrogen-positive breast cancer in
postmenopausal women [6,7]. Femara® (2.5 mg), amongst other similar
formulations, is a clinically established oral tablet product of LTZ. The
drug is given in a low oral dose because of its adverse effects, including
arthralgia, bone fragility, and hypercholesterolemia [8], with recent
reports indicating that hormone fluctuations due to administration of
LTZ may cause mental depression [9]. The large volume of distribution
of LTZ is responsible for the low plasma levels of the drug, and the
numerous adverse effects, which may compromise the overall ther-
apeutic benefit [10].
Developing prolonged release parenteral infusions or intratumoral
injections of LTZ can be highly advantageous for minimizing the po-
tential of adverse effects and increasing the localization of the drug at
the cancer site. However, the design of such alternative formulations of
LTZ is challenged by the poor aqueous solubility of the drug, and the
shortage of information related to its stability in aqueous dosage forms.
Biodegradable drug delivery systems, including nanotechnology-
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based formulations, have attracted considerable attention over the past
few decades. These delivery systems can overcome poor solubility,
enhance therapeutic efficacy, and reduce the adverse effects of a wide
variety of therapeutic molecules [11–14]. Recent development of LTZ
formulations utilizing polymeric systems has been reported, through
employing chitosan nanoparticles [15], chitosan-lipid nanocomplexes
[16], dendrimers [17,18], and other polymers like poly(d,L-lactide)
(PDLLA) to prepare microparticles [19] or nanoparticles [20]. In our
laboratory, we adapted an aerosol generating mechanism to produce
monodisperse biodegradable polycaprolactone (PCL) and PDLLA LTZ
particles. The resultant formulations exhibited superior drug entrap-
ment efficiencies (94–97%), gradual drug release over one month, and
in vitro cytotoxicity against the cancerous breast cells MCF-7 [19].
As an alternative to polymers, surfactants such as phospholipids
(e.g., naturally derived phosphatidylcholines) or synthetic non-ionic
surfactants (e.g., Tweens and Spans) have been used to design liposome
or noisome formulations, respectively. Amongst many types of nano-
carrier delivery systems, liposomes have been reported for the earliest
success in anticancer therapy, and several liposome-based anticancer
formulations have been commercialized [21,22]. For example, Doxil® is
an intravenous injection of PEGylated liposomes loaded with doxor-
ubicin; this formulation proved to be efficacious in the management of
solid tumours, haematological malignancies and AIDS-related Kaposi's
sarcoma [23,24].
Unfortunately, liposomes are unstable carriers, because of liability
of their phospholipid molecules to hydrolysis and oxidation, with
concomitant vesicle aggregation and leakage of the originally en-
trapped drug. Niosomes (non-ionic surfactant vesicles) are stable al-
ternatives to liposomes [25,26]. Azizi and Norouzian (2015) have de-
veloped a PEGylated niosomal formulation of LTZ, and reported that
the niosomal formulation was toxic to MCF-7 cancerous cells in vitro
[27]. Thin film hydration method is one of the most extensively studied
conventional techniques and has been reported to generate multi-
lamellar niosomes [28]. Unfortunately, liposomal and niosomal for-
mulations prepared using such conventional techniques (e.g. thin film
hydration) are difficult to scale up and may demonstrate instability
manifestations during their storage as aqueous dispersions.
Proniosomes are stable dry powder precursors of niosomes, offering
higher stability profile and greater potential for large scale manu-
facturing. Proniosomes are carbohydrate particles coated with non-
ionic surfactants that can generate niosome vesicles upon addition of
aqueous phase with shaking [29–32]. Scaling up studies of proniosomes
have been conducted by compressing the proniosome powders into
tablets [33], or by the large-scale generation of nano-niosomes from
proniosomes via hydration followed by high pressure homogenization
[34]. Niosomes generated using proniosome technology may offer po-
tential for delivery via a range of routes such as oral [33,35,36], par-
enteral [37], and pulmonary [30].
In the present study, we designed LTZ-loaded proniosome for-
mulations that can readily be hydrated into niosomes and reduced to
the nano size via probe-sonication. The nano-niosomes were thoroughly
characterized in terms of particle size and size distribution, zeta po-
tential, and ability to entrap LTZ and sustain its release. The profile of
drug release was studied over a prolonged period of one month, and the
release mechanism was identified and described by considering the
following models: zero-order, first order, Higuchi, Korsmeyer-Peppas,
Weibull, Hill equation and Hixon Crowel [38]. Furthermore, the pro-
niosome powder formulations were characterized in terms of pronio-
some surface morphology, and drug content and crystallinity. To the
best of our knowledge, this is the first study that employed a slurry-
based proniosome technology to incorporate LTZ in controlled release
formulations. It is hypothesized in this study that niosomes generated
with this method would have potential, subject to further investiga-
tions, to be used as an intratumoral injection, with the aim of providing
an alternative to the commercially available Femara® oral tablets.
2. Materials and methods
2.1. Materials
Cholesterol (CH), carbohydrate carriers (sorbitol and sucrose),
Tween® 80 (T80; polysorbate 80; polyoxyethylene sorbitan mono-
oleate) and dialysis bags (cut-off 12,000 Da) were all purchased from
Sigma-Aldrich, Germany. Chloroform and acetonitrile were both of
HPLC-grade and purchased from Merck Co., Germany. Transcutol® HP
was supplied by Gattefossé, Lyon, France. Letrozole (LTZ) was bought
from Jiangsu Ainty Handsome CO., LTD, China. All materials were used
as received without further modification.
2.2. Methods
2.2.1. Preparation of niosomes using thin film hydration
Tween® 80 (T80) and other lipid phase components such as cho-
lesterol (CH) and letrozole (LTZ) were mixed and dissolved together in
chloroform (10 ml) within a round bottomed flask (25 mg/ml). The
flask was attached to a rotary evaporator (Buchi Rotavapor,
Switzerland) for 2 h to allow the organic solvent to evaporate under
reduced pressure and leave a thin lipid film on the inner wall of the
flask [28]. The flask was left under fume hood overnight to allow for
evaporation of solvent residues, if any. The film was then hydrated with
deionized water (60 °C) followed by mechanical shaking (Julabo®
shaking water bath, USA) for 30 min to ensure complete lipid hydration.
The formulation was left on the bench overnight before performing
further processing or characterization. The composition of all for-
mulations is elucidated in Table 1.
2.2.2. Preparation of niosomes using the slurry-based proniosome
technology
Proniosomes were prepared by adapting the slurry-based prolipo-
some method we previously introduced [39]. Sucrose or sorbitol carrier
particles were sieved using a sieving set (Fisher Scientific, UK) to obtain
a size range of 250–500 μm. Proniosomes were prepared by coating T80
and CH (250 mg total lipid phase), in various molar ratios (Table 1)
onto sucrose or sorbitol carrier particles, in 1:5 w/w lipid to carrier and
by incorporating LTZ into the lipid phase (5% or 30% of the lipid
phase). This was achieved by loading the carbohydrate carrier particles
(sucrose or sorbitol) into a round bottomed flask. T80, CH and LTZ were
dissolved in ethanol separately and poured directly on the carbohy-
drates carriers to create a slurry. The flask containing the alcoholic
slurry (333 mg/ml) was attached to the rotary evaporator and partially
immersed into a water bath (45 °C), allowing ethanol to evaporate
under rotation and reduced pressure for 2 h. The flask was placed under
the fume hood overnight. The proniosomes were collected from the
flask and stored in glass vials at 4 °C for subsequent processing and
characterization. The composition of all proniosome formulations is
Table 1
Different formulations for niosomes and proniosomes.
Formulation CH:T80 Carrier Loaded with
LTZ
Hydration Temperature
(°C)
F1
F1B
1:1
1:1
N/A
N/A
Yes
No
60
60
F2 1:0.5 Sorbitol Yes 60
F3 1:0.5 Sucrose Yes 60
F4 1:1 Sorbitol Yes 60
F4B 1:1 Sorbitol No 60
F5 1:1 Sucrose Yes 60
F5B 1:1 Sucrose No 60
F6 1:1.5 Sorbitol Yes 60
F7 1:1.5 Sucrose Yes 60
F8 1:2 Sorbitol Yes 60
F9 1:2 Sucrose Yes 60
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shown in Table 1. Niosomes were generated from proniosome granules
(containing 1.5 mg LTZ) by placing the granules in an Eppendorf tube
and adding deionized water (1 ml; 65 °C) with vortex-mixing for 2 min.
The tubes were then placed in a Julabo® shaking water bath set at 60 °C
for 30 min. The formulations were left at room temperature overnight
to allow for niosome stabilization.
2.2.3. Vesicle size reduction via sonication
Following the generation of niosomes from thin films or pronio-
somes, the tubes containing niosomes were placed in a Branson® water
bath sonicator (Branson Ultrasonics, Connecticut, USA) for 30 min at
room temperature to facilitate deaggregation of aggregated vesicles.
This was followed by probe-sonication (Branson® probe sonicator,
Branson Ultrasonics, Connecticut, USA) for 6 min, and by allowing for
intermittent cooling, every 30 s for 2 min to avoid overheating of the
formulations above 70 °C. The samples were spun for 10 min to sedi-
ment the titanium particles leaching from the probe of the sonicator.
The samples were then aspirated from the supernatant for subsequent
characterization studies.
2.2.4. Particle size analysis and zeta potential studies of niosomes
The hydrodynamic diameter and size distribution (polydispersity
index; PDI) of all niosome formulations were analyzed via dynamic
light scattering using the Nano ZS Zeta Sizer instrument (Malvern
Instruments Ltd, UK) at 25 °C. For each sample, three independent
measurements using three different batches were performed. Zeta po-
tential analysis was conducted using Laser Doppler Velocimetry by
employing the same instrument at 25 °C following selection of the re-
levant software option.
2.2.5. Drug entrapment determination using Ultraperformance Liquid
Chromatography (UPLC)
Reliable determination of drug entrapment depends on adequate
separation of the entrapped drug from the unentrapped fraction. In
other words, one obstacle in drug entrapment determination is the
concomitant sedimentation of the vesicles (containing the entrapped
drug) with the unentrapped free drug particles upon centrifugation.
This commonly results in significantly overestimated drug entrapment
efficiencies [39]. In one of our earlier studies, the employment of
deuterium oxide (i.e. heavy water) has demonstrated to be an appro-
priate dispersion medium to separate vesicles from the unentrapped
fractions of another lipophilic drug upon centrifugation [39]; therefore,
the utilization of deuterium oxide to better separate LTZ in our ex-
periments was also investigated. Two separation methods were used
before the determination of LTZ entrapment efficiency in the niosomes,
by using two different dispersion media. The separation of entrapped
drug from the unentrapped (free) fraction in this study was adapted
from the procedure we previously published with liposomes entrapping
beclometasone dipropionate [39]. One of the two methods is the se-
paration from vesicles dispersed in deionized water (DW) followed by
centrifugation; thus, vesicles (with entrapped drug) would presumably
sediment whilst unentrapped drug remains in the supernatant (Fig. 1A
and B). In fact, this method has shown to provide an overly estimated
entrapment in liposomes due to the concomitant sedimentation of li-
posome vesicles (incorporating the drug) and the free (unentrapped)
insoluble drug crystals [39].
The second method, which has shown to be more accurate in our
previous studies, was implemented by hydrating the proniosomes with
deuterium oxide (i.e. D2O; heavy water), followed by centrifugation at
optimum conditions (Fig. 1A, C). The use of the higher density medium
(i.e. D2O) may facilitate the separation of niosomes so that, upon cen-
trifugation, vesicles tend to float on the surface where they can be as-
pirated to quantify the entrapped hydrophobic drug. According to our
previous findings using this method, the unentrapped drug is sedi-
mented in the form of solid particles that have a higher density than the
lipid vesicles [39]. The difference between the two separation methods
is illustrated in Fig. 1. Thus, for each formulation, two sets of samples
were hydrated using deionized water (DW) or heavy water (D2O). Both
sets of samples were sonicated as described earlier, and then placed in
the Thermo Scientific® Micro 21R centrifuge (Thermoscientific, USA),
for 45 min at 15,500×g at 4 °C, to separate the niosomes (including a
proportion of LTZ) from the free (unentrapped) drug. The separation in
case of D2O following centrifugation was ascertained using light mi-
croscopy by viewing samples from the floating creamy layer, the sedi-
ment, and the continuous phase in between the two regions.
For the deuterated water (D2O) method, the cloudy floating layer
(100 μl) was carefully aspirated and further diluted with acetonitrile
(1.9 ml) in order to disrupt the vesicles and solubilize the entrapped
LTZ. The resultant solution samples were vortex-mixed for 2 min and
filtered through Polytetrafluoroethylene (PTFE; 0.2 μm; Sigma Aldrich,
Germany) before loading into Waters® Ultraperformance Liquid
Chromatography (UPLC) vials for subsequent drug quantification using
UPLC (Waters, Illinois, USA) at 240 nm by following a method we re-
cently published [20].
• For the first method, using deionized water (DW) as a dispersion
medium:
=
−
EE %
Total drug amount in the sample Drug amount in the 
supernatant
Total drug amount in the sample
x
( )
100 (1)
• For the second method, using heavy water (D2O) as dispersion
medium:
=EE % Drug amount in the floating top layer i e niosome layer
Total drug amount in the sample
x
( ) ( . . )
100 (2)
2.2.6. X-ray diffraction studies
The X-ray Diffraction (XRD) analysis of proniosome powders
(manufactured using the slurry method) and LTZ raw powder was
conducted at room temperature by using the X-ray diffractometer D8
Advance with CuK alpha radiation source (Bruker Co., Germany). The
diffraction data were collected over the angular range of 5–60° with a
step size of 0.05° and a counting time of 60 ms. The other various
components were assigned through auto-fitting in the instrument using
the DIFFRAC.EVA software (Bruker Co., Germany). In this experiment,
LTZ-loaded proniosomes were prepared with a drug concentration of up
to 50% (w/w) of the total lipid, taking into account that the con-
centration of LTZ used in the formulations might be below the limit that
can be detected by the instrument. Furthermore, LTZ alone was pro-
cessed in the rotary evaporator with chloroform to end of up with a dry
product, for subsequent comparison with the crystallinity of LTZ in-
corporated into the proniosome powders.
2.2.7. Differential scanning calorimetry (DSC)
Thermal properties of the proniosomes powders were studied using
differential scanning calorimetry (DSC) by employing the DSC 8000
instrument equipped with an intra-cooling system Intra-cooler II
(PerkinElmer, USA). All samples were analyzed at a heating rate of
10 °C/min in the range of 30–220 °C.
2.2.8. Scanning electron microscopy (SEM)
Proniosome powder samples were visualized using scanning elec-
tron microscopy (SEM; JSm 6100 JEOL, Tokyo, Japan). The samples
were mounted onto the SEM stub and coated with gold film (200 nm
thickness). The experiments were performed under reduced pressure
(0.001 mmHg) and images were taken to evaluate the morphology of
the proniosome particles.
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2.2.9. Assessment of drug release from niosomes in vitro
Niosome formulations were evaluated for the release rate of LTZ
using the membrane diffusion technique. Dialysis bags (cut-off
12,000Da, Sigma, Germany) were used as ‘donor compartment’ by in-
cubation for 24 h in a phosphate buffer (containing 20% Transcutol as
co-solvent) to maintain a sink condition, at a physiological pH of 6.8
[40]. The niosomes containing LTZ were pipetted into the dialysis bags,
which were immersed in phosphate buffer to end up with a final volume
of 100 ml. The bags were kept in a shaking water bath (Julabo®, USA)
for one month at 37 °C ± 1 and 100 rpm. A comparative sample
consisting of LTZ suspension was prepared by weighing an equivalent
amount of LTZ and mixing it in phosphate buffer containing 20%
Transcutol. The mixture was vortexed for 10 min and then placed in a
dialysis bag and clipped before placing it in the recipient medium.
At time intervals, 3 ml of the dissolution medium was taken and
replaced with an equal volume of fresh drug-free medium. The samples
were separately measured using UPLC, and results were presented as
mean values of three different runs using three different niosome bat-
ches. The release data were fitted to a range of models, which were
zero-order, first order, Higuchi, Korsmeyer-Peppas, Weibull, Hill
equation, and Hixon Crowell [38], in order to determine the me-
chanism of drug release. The correlation coefficients for the different
release profiles were also determined. All kinetic profiling studies were
conducted using KinetDS3 software, where the r2 values were calcu-
lated by regression analysis of each model [38].
2.2.10. Statistical analysis
The results were reported as mean ± standard deviation for three
measurements conducted on three different batches. The difference
between the groups was regarded to be significant when P values were
equal to or smaller than 0.05. These measurements were conducted
using the Sigma plot software (version 12.0) by performing the t-tests
and one-way analysis of variance (ANOVA) for two groups and more
than two groups, respectively.
3. Results and discussion
3.1. Size of niosomes
Table 1 represents all formulations investigated for size analysis
including those made by the conventional thin-film hydration method
(F1 and F1B), and niosomes made using the proniosome technology
(F2-F9). As shown in Table 2, the effect of drug inclusion on the mea-
sured size and polydispersity was investigated for thin-film niosomes
(F1 and F1B) and for niosomes generated from proniosomes (F4 and
F4B, F5 and F5B). The effect of LTZ inclusion in the formulations was
studied for both carriers (sorbitol and sucrose) but only for CH:T80
(1:1) (Table 2) because this ratio is commonly used in published re-
ports, due to established formulation stability and minimized drug
Fig. 1. Niosomes separation using deionized water
(DW; H2O) or deuterated water (D2O) as hydration
media. (A) The dispersion prior to centrifugation
where niosomes were hydrated and are uniformly
distributed in the suspension. (B) Following cen-
trifugation of the dispersion in DW, niosomes (con-
taining entrapped drug) and the free (unentrapped)
LTZ crystals are sedimented at the bottom of the
tube. (C) Three distinctive layers are present upon
centrifugation of the dispersion in D2O; the top
floating layer represents the niosomes (with en-
trapped drug) while the free crystals are sedimented.
Trace fraction of the drug in its water-soluble form is
associated with the clear aqueous phase in the
middle region.
Table 2
Size analysis of LTZ-loaded and unloaded niosome formulations.
F# Carrier Particle size (nm) PDI
F1B N/A 60.4 ± 1.6 0.20 ± 0.008
F1 N/A 120.3 ± 21.5 0.20 ± 0.035
F4B Sorbitol 85.9 ± 0.6 0.14 ± 0.010
F4 Sorbitol 148.4 ± 9.8 0.16 ± 0.021
F5B Sucrose 93.5 ± 5.2 0.16 ± 0.013
F5 Sucrose 139.2 ± 2.5 0.17 ± 0.057
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leakage [35,41–45]. Inclusion of LTZ caused the hydrodynamic size to
increase significantly (p < 0.05) with only a slight trend of increment
in PDI (Table 2). The increase in hydrodynamic size as a result of drug
incorporation was most prominent for vesicles prepared using thin-film
hydration (F1B and F1), so that size was doubled (Table 2). By contrast,
the increase in particle size, caused by drug inclusion, was least when
vesicles were generated from proniosomes using sucrose carrier (F5B
and F5; Table 2). The increase in niosome size as a result of drug in-
clusion has previously been reported [46–48]. Size increment might be
attributed to an increase in the hydrophobicity of particle surfaces,
promoting aggregation and/or fusion of the individual particles [30]. It
has also been hypothesized that materials incorporated into surfactant
vesicles may interact with the polar headgroups of the surfactant,
causing repulsion of the surfactant bilayers and increasing vesicle size
[46,47].
Table 3 demonstrates a comparison between all formulations that
included LTZ, hence, the effect of carrier type and lipid phase compo-
sition of the niosomes was studied. Generally, both hydrodynamic size
and PDI were affected significantly (p < 0.05) by the changes on each
formulation. Overall, Table 3 demonstrate that particle size of the
generated niosomes using the conventional or proniosome-based tech-
niques ranged between 100 and 194 nm. Furthermore, the vesicles
generated from proniosomes were similar in size to those made using
the conventional thin-film method (p > 0.05). In addition, regardless
of carrier type, the increment of CH proportion in the formulation
caused an increase in particle size (Table 3), possibly through in-
creasing the hydrophobicity of the particles, promoting aggregation, as
described earlier.
The size distributions, expressed as PDI, were below 0.3 (Table 3),
indicating that niosomes had low polydispersity, regardless of for-
mulation composition [44]. Niosomes had the lowest PDI when CH:T80
was 1:1, suggesting that the equimolar ratio is most appropriate for
having vesicles with narrow size distribution (Table 3). Previous reports
demonstrated that maximum niosome stability is achieved when CH
and surfactants are incorporated in 1:1 mol ratio [48]. In general,
niosomes generated from sucrose-based proniosomes showed similar or
lower PDI when compared with vesicles generated from sorbitol-based
proniosomes.
The particle size measurements reported in the current study come
in agreement with previous literature reports. The mean diameter re-
ported for niosomes prepared using T80 and CH followed by sonication
was below 300 nm, with a PDI of 0.49 [49]. Additionally, T80 niosomes
were found to exhibit smaller particle size when compared to other
Tween surfactants [50], justifying the use of T80 in the present study.
3.2. Zeta potential analysis
Zeta potential can be used as an indicator of the extent of repulsive
forces between the dispersed nanoparticles [42]. In general, zeta po-
tential of niosomes was found to be negative for all formulations in a
manner that was dependent on formulation (Fig. 2A). The zeta
potential, in terms of charge intensity, of all niosomes was found to be
less than −30 mV (Fig. 2A). Niosomes generated from sucrose-based
proniosomes had equal or lower zeta potential values than vesicles
generated from sorbitol-based formulations (Fig. 2A). To study the in-
fluence of LTZ incorporation on zeta potential, we used CH:T80 (1:1) as
the standard lipid composition for thin-film made formulation and
proniosome-generated vesicles (sucrose-based and sorbitol-based)
(Fig. 2B). Our investigation indicated that LTZ had a trend of in-
tensifying the negativity of surface charge for proniosome-made for-
mulations; this, however, was statistically insignificant (P˃0.05).
However, for thin-film made niosomes, the effect of LTZ at increasing
the charge intensity was tremendous (P < 0.05), because the drug-free
vesicles were found to have a very mild negative zeta potential
(Fig. 2B).
3.3. Drug entrapment efficiency in niosomes
Drug entrapment was determined following separation of un-
entrapped drug from that entrapped in the vesicles. Separation can be
achieved using numerous techniques. A traditional technique com-
monly reported in literature is implemented by centrifuging the vesicle
dispersion in order to sediment the vesicles (with the drug entrapped)
and leaving an aqueous supernatant where the unentrapped drug is
presumably located [42,43,49,51]. Although this technique is widely
and commonly used, research investigations have demonstrated it to be
inaccurate when the incorporated drug is hydrophobic [39,52,53]. In
aqueous phase, hydrophobic drugs tend to form crystals with density
similar to that of vesicles, resulting in concomitant sedimentation of the
unentrapped drug crystals with the vesicles containing the entrapped
drug upon centrifugation [52]. Thus, the sedimented crystals are falsely
counted as entrapped drug, resulting in overestimated drug entrapment
in vesicles [39]. We resolved this problem and optimized the separation
in our earlier studies (using liposomes as model vesicles) by dispersing
the liposomes in deuterium oxide (heavy water; D2O) instead of water.
Centrifugation in D2O using optimum conditions (i.e. temperature,
speed and duration) causes preferential localization of the vesicles on
the surface of dispersion as a floating creamy layer, whilst solid drug
particles tend to sediment as demonstrated using light microscopy
(Fig. 3). Furthermore, centrifugation conditions depend highly on type
and density of drug crystals/solid particles [53]; thus, the centrifuga-
tion conditions apply here for LTZ loaded into niosomes may not apply
on other hydrophobic drugs and different vesicle compositions. It is
important to bear in mind that the use of D2O was confined to the
entrapment studies; this solvent is not part of the preparation protocol
owing to its dose-related toxicity [54] and high cost.
In the present study, we reported the entrapment efficiency of LTZ
as ‘actual entrapment’ using D2O, and for comparison, we also de-
termined the ‘apparent entrapment’ using DW as dispersion medium
(Fig. 2A). LTZ was initially incorporated into the formulations in excess
(30% w/w) aiming to achieve maximum entrapment, and that was
compared with 5% w/w loading. The ‘apparent entrapment’ of LTZ was
similar for both loadings whilst the ‘actual entrapment’ tended to be
either similar for both loadings, or different between the two loadings,
but with no clear trend or rule (Fig. 4A). Noteworthy, in most for-
mulations, the ‘actual entrapment’ was higher for the higher loading
(30%) compared to the lower loading (5%) (Fig. 4A). This is contrary to
our expectation since entrapment is calculated here as ‘entrapment ef-
ficiency’ (i.e. the percentage proportion of entrapped drug) which is
expected to be higher when the loaded drug amount is lower. The
unexpected finding might be attributed to the presence of some LTZ in
its water-soluble form in the aqueous region between the floating
creamy layer (i.e. niosome layer) and the drug sediment at the bottom
(Fig. 3). This water-soluble fraction of LTZ was a significant proportion
when the lower drug loading (i.e. 5%) was used.
Fig. 4A also demonstrates that the apparent drug entrapment effi-
ciencies were significantly higher (P < 0.5) than the actual
Table 3
Size analysis, polydispersity index, and zeta potential for all formulations.
F#
CH:T80 Carrier Particle size (nm) PDI
F1 1:1 N/A 120.3 ± 21.5 0.197 ± 0.035
F2 1:0.5 Sorbitol 194.3 ± 3.8 0.268 ± 0.008
F3 1:0.5 Sucrose 146.8 ± 29 0.185 ± 0.048
F4 1:1 Sorbitol 148.4 ± 9.8 0.159 ± 0.021
F5 1:1 Sucrose 106.8 ± 13.3 0.168 ± 0.056
F6 1:1.5 Sorbitol 117.4 ± 5.3 0.283 ± 0.031
F7 1:1.5 Sucrose 105.1 ± 4.2 0.197 ± 0.036
F8 1:2 Sorbitol 102.6 ± 3.2 0.270 ± 0.028
F9 1:2 Sucrose 100.3 ± 6.3 0.250 ± 0.033
Values expressed as Mean ± SD (n = 3).
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entrapment efficiencies. The maximum actual entrapment was achieved
upon using a surfactant to cholesterol ratio of 1:1 and 1.5:1, regardless
of carrier type. The least entrapment was reported to be in formulations
F2 and F3, in which the ratio of CH to surfactant was 1:0.5 (Table 1),
highlighting the importance of having high surfactant concentrations in
the formulations in order to maximize drug entrapment in the vesicles.
Thus, equal mole proportions between the surfactant and cholesterol
seems desirable for producing niosomes with appropriate size, size
distribution (Table 3) and LTZ entrapment efficiency (Fig. 4A), agreeing
with previous observations using conventional niosomes [48]. Inter-
estingly, the increase in the ratio between the non-ionic surfactant and
cholesterol beyond 1:1 has decreased the drug entrapment. This might
be attributed to that high Tween 80® concentrations have resulted in
presence of some surfactant molecules independently in the continuous
aqueous phase, increasing the solubility of LTZ in the external aqueous
phase at the expense of the niosome bilayers. Alternatively, the pre-
sence of high surfactant concentrations may have caused the vesicles to
become ‘leaky’, resulting in lower drug entrapment. Amongst the
Tween surfactants, Tween 80 in noisome formulations was reported to
offer the highest entrapment efficiency [55], justifying its use in this
study.
3.4. Influence of storage on LTZ entrapment
Niosome instability during storage is commonly manifested by the
increase in particle size and polydispersity owing to vesicle aggregation
or fusion; this is accompanied by drug leakage from the vesicles [48].
Size and polydispersity increments are qualitative measures of vesicle
stability, and can be associated with limitations such as the range of
particle size that can be accurately measured by each instrument and
the artifacts associated with every size analysis technique. For this
reason, we decided to study the entrapment of LTZ as a quantitative
measure for niosome stability; hence the greater the drug leakage (i.e.
the lower the entrapment), the lower the formulation stability.
We determined LTZ entrapment after three months of storage at 4 °C
or room temperature (RT) and compared these findings to the entrap-
ment determined for freshly prepared niosomes (Fig. 4B). Studies using
the traditional separation technique with DW (i.e. apparent entrapment
studies) showed that differences in drug entrapment after storage were
minimal compared to the freshly prepared vesicles (Fig. 4B). By con-
trast, the ‘actual entrapment’ studies confirmed that effective separa-
tion is important for providing trustable entrapment findings that can
be translated into reliable stability studies. Importantly, actual drug
entrapment studies revealed that storage of niosomes causes marked
leakage of LTZ (i.e. lower actual drug entrapment efficiencies), with
more drug losses (i.e. lower entrapment values) at RT compared to 4 °C
(Fig. 4B). For example, in F5 formulation, the actual entrapment effi-
ciency decreased from around 74% in the freshly prepared vesicles to
less than 20% when the formulation was stored at RT (Fig. 4B). These
findings indicate that niosomes should be used as soon as they are
prepared, and if storage is necessary, then it should happen at low
temperature (e.g. 4 °C). Importantly, the stability study was conducted
on niosomes in their aqueous dispersion form not on the proniosomes in
their powder form. Our initial investigations showed that, storage of
proniosome powders at 4 °C or RT did not affect drug entrapment in
accordance to a parallel study we conducted on one these formulations
(data not shown). In the future, a broader stability investigation will be
implemented to explore more about the storage of proniosome pow-
ders.
3.5. Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) was carried out for LTZ-
loaded proniosomes versus the pure LTZ powder. LTZ alone showed a
sharp endothermic peak corresponding to its melting point with an
onset of 185 °C, illustrating the typical crystalline nature of the drug.
This peak was persistent even upon processing LTZ in chloroform (in
the rotary evaporator) to simulate the process of niosomal preparation
(data not shown). Importantly, this distinctive peak of LTZ was absent
Fig. 2. A. Zeta potential difference between
blank (i.e. drug-free) niosomes and LTZ-
loaded niosomes. Error bars represent
standard deviation from three independent
experiments using three different pronio-
some batches. B. Zeta potential for all for-
mulations. Error bars represent standard
deviation from three independent experi-
ments using three different proniosome
batches.
Fig. 3. Optical microscopy images for the three distinctive layers obtained by
using heavy water (D2O) as the hydration medium for the niosomes. Optical
microscopy images were evaluated under standard and polarized lenses (left
and right images, respectively). A. The top images are for the floating creamy
layer, representing a confirmation for the generation of the vesicles with
minimal to no crystals deposition out of the niosomes. B. The middle image is
for the continuous aqueous phase where it contains no vesicles or crystals, but a
trace fraction of soluble LTZ. C. The bottom image is for the sedimented un-
entrapped crystals of LTZ.
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in all proniosome formulations, regardless of the carbohydrate carrier
type (i.e. sucrose or sorbitol) (Fig. 5), indicating conversion of LTZ into
its amorphous form. These observations were ascertained further in the
subsequent section using XRD. Furthermore, carbohydrate carriers
(sorbitol and sucrose) also exhibited sharp melting peaks, indicating
that their crystallinity was not affected by coating with lipids such as
Tween 80 and cholesterol. It was also noted that different carbohydrate
carriers had different melting temperatures, with minimal effect of lipid
composition on the melting temperatures of the carbohydrate carriers
(Fig. 5).
3.6. X-ray diffraction (XRD) analysis
X-ray diffraction (XRD) was used to evaluate the crystallinity
characteristics of LTZ in the proniosome powders. XRD showed that
LTZ crystals were detected as sharp and distinctive peaks when eval-
uated before dissolving the drug in chloroform or even after treating
them in the rotary evaporator (simulating the process by which pro-
niosomes were formulated). Hence, using XRD, there was no apparent
effect of the organic solvent on the crystallinity characteristics of LTZ.
Furthermore, studies on proniosomes showed no distinctive peaks of
LTZ in the proniosome formulations, regardless of carbohydrate carrier
type (Fig. 6). These findings consolidated our DSC results, where the
characteristic peaks of LTZ were absent when it was incorporated into
proniosome powders. The current results are in accordance with pre-
vious studies that compared the physical state of poorly-water soluble
drugs (e.g. ezetimibe, nateglinide, vinpocetine) incorporated into pro-
niosome formulations [36,56,57]. In our previous investigations using
slurry-based proliposomes, we also found that the hydrophobic drug
beclometasone dipropionate becomes amorphous upon incorporation
into phospholipid surfactants with CH and using carbohydrate carriers
like sorbitol, lactose monohydrate and mannitol [53], indicating that
proniosomes and proliposomes can abolish the crystallinity of the in-
corporated hydrophobic drug.
3.7. Scanning electron microscopy (SEM) studies
Scanning electron microscopy (SEM) images of proniosomes are
presented in Fig. 7. It can be observed that surface appearance depends
on type of carrier. For instance, the surface of sorbitol particles, prior to
coating with lipids, was highly porous and spiky. This was changed into
apparently smoother and less spiky upon coating with the lipids, in-
dicating that the porous structure of the carrier was coated successfully
with the lipid. By contrast, sucrose particles prior to coating were ap-
parently smooth and non-porous. This was changed upon coating with
the lipid, creating what looked to be a flaky surface. For comparison of
the surface appearance of proniosomes with that of the thin-film, we
also imaged the thin-film using SEM. Thin-films of surfactant, CH and
LTZ had a flaky surface that is similar to that of sucrose-based pro-
niosomes. Parallel to this study, we conducted drug content analysis to
assess whether the morphology of the carbohydrate carriers (porous
surface of sorbitol and flatty surface of sucrose) would affect the
Fig. 4. A. Entrapment efficiency differences when 30% LTZ and 5% LTZ loadings were compared. Data are mean values (n = 3 ± SD). B. ‘Apparent entrapment’ and
‘actual entrapment’ efficiencies during storage at different temperatures. Data are mean values (n = 3 ± SD).
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accommodation of LTZ on the carrier surfaces. All proniosome for-
mulations accommodated 95–98% of LTZ originally included (data not
shown), indicating that surface morphology had no effect on drug
content. Interestingly, the similarity of surface morphology of sucrose-
based proniosomes and that of thin-film seemed to end up with nio-
somes generally having lower PDI values compared to niosomes gen-
erated from sorbitol-based proniosomes (Table 3).
3.8. In vitro release profile of LTZ
The formulations selected for the release studies were those pro-
viding the highest drug entrapment efficiencies and best storage sta-
bility; these characteristics were best achieved when CH to surfactant
ratio was 1:1. Thus, F4 and F5 were compared against LTZ suspension
and F1 (the traditional niosomal formulation made by the thin-film
method) (Fig. 8). The drug release profiles were studied over a period of
one month, and the mechanism of release was fitted against a number
of models, which are zero-order, first-order, Higuchi, Korsmeyer-
Peppas, Weibull, Hill equation and Hixon Crowell.
All F1, F4 and F5 formulations were found to have similar release
patterns, in which a burst of drug was released without a detectable lag-
time in the initial phase over the first 24 h (Fig. 8A). The percentage of
drug release reached approximately 53 ± 0.5%, 65 ± 1% and
59 ± 3% for conventional niosomes, sorbitol-based niosomes and
sucrose-based niosomes, respectively. These were faster than the re-
lease of LTZ from the suspension formulation that required a longer
duration of one week to reach the same release levels (Fig. 8B) de-
monstrated by niosomes over 24 h (Fig. 8A), possibly because the so-
lubility of LTZ was the lowest in the suspension formulation. The drug
release was found to happen very slowly after the first 24 h (Fig. 8).
Importantly, the cumulative release from niosomes generated from
proniosomes was higher than that from the conventional vesicles after
24 h (Fig. 8); however, after a week duration, the release from con-
ventional niosomes reached a very similar level to that of proniosomes-
generated niosomes (Fig. 8).
When considering the drug release levels after a month, all for-
mulations have released almost 100% of the originally entrapped LTZ
(Fig. 8C). The difference in release patterns between conventional ve-
sicles and those generated from proniosomes is attributed to different
formulations. It seems that sugars have affected the initial packing of
the niosomal bilayers, contributing to the faster drug release from the
proniosome-made formulations (Fig. 8A and B).
Table 4 summarizes the kinetic profiles in r-squared (r2) values,
which were obtained from linear regression analysis for all
Fig. 5. A. DSC Thermographs of sorbitol-based proniosomes. The absence of LTZ distinctive peak at 185 °C indicates drug conversion into the amorphous form. B.
DSC thermographs of sucrose-based proniosomes. The absence of LTZ distinctive peak at 185 °C indicates drug conversion into the amorphous form.
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formulations as well as for LTZ suspension as a control comparative
formulation. The results showed that proniosomal formulations were
consistently best fitted with the Higuchi model, which explains that LTZ
diffuses from the vesicles in a slower rate as the distance for diffusion
increases. Moreover, it was noted that the formulations followed a bi-
phasic release pattern, in which a surge of LTZ was released into the
medium in a fast rate, which was followed by a sustained slower rate of
release for the remaining period of investigation (Table 4).
Our present findings are in agreement with those presented by
Kamboj et al. (2014) who reported that drug release from niosomes was
best fit with Higuchi model followed by Korsmeyer-Peppas model [43].
This confirms that the loaded drug concentration is higher than drug
solubility in the niosomal suspension; this provides perfect sink con-
ditions at the noisome's surface. Consequently, the system shows a
prolonged release time known as pseudo-steady-state conditions
leading to drug diffusion form niosomes compared to solid suspension.
Furthermore, diffusion-based release pattern was reported for zidovu-
dine-loaded niosomal formulations [49]. Biphasic release from nio-
somes was also reported for ciprofloxacin, with a rapid initial release
followed by a slower phase [58].
The fatty acid chain characteristics of the surfactant is influential on
drug release from vesicles. The longer the chain, the slower the drug
release, which is attributed to the rigidifying effect of long chain sur-
factants on niosomal membranes [49]. In this study we focused on
carbohydrate carrier type and surfactant to CH ratio. Future in-
vestigations should explore the effect of type of non-ionic surfactant on
physicochemical properties of niosomes generated from proniosomes
made using the slurry-based method.
Fig. 6. A. XRD graph for sorbitol based proniosome formulations. B. XRD graph for sucrose based proniosome formulations.
Fig. 7. A. Scanning electron micrographs for sorbitol
based proniosomes. (1) Commercial samples of sor-
bitol demonstrate a surface that looks like crystals
that are sharp and rough. (2) Proniosomes prepared
using sorbitol, in which the surface is similar but
with less well-defined features. (3) and (4) are the
same images as (1) and (2), respectively but with
higher magnifications. B. Scanning electron micro-
scopy images for sucrose-based proniosomes. (1)
Commercial sucrose samples prior to coating with
lipid appear smooth and well defined. (2)
Proniosomes prepared using sucrose and coated with
lipids has a surface that is flaky and rigid. (3) and (4)
are the same images as (1) and (2), respectively, but
with greater magnifications. C. Thin lipid films con-
taining no carbohydrate carriers in two different
magnifications.
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4. Conclusion
Novel proniosome formulations incorporating the anticancer drug
LTZ were designed using sorbitol or sucrose carrier particles, by em-
ploying the ethanol slurry method. Niosomes readily generated nio-
somes upon addition of aqueous phase, and as for conventional nio-
somes (made using thin film-hydration), the vesicles were reduced in
size successfully to the nano range (approx. 100–200 nm) via probe-
sonication. Sorbitol-based proniosomes were found to generate nio-
somes that are slightly larger than conventional niosomes and those
generated from sucrose-based proniosomes. All niosomes had negative
zeta potential values, regardless of carrier type and lipid composition.
Increasing the surfactant concentration made the niosomes smaller in
size but did not affect the zeta potential. The lowest polydispersity and
highest ‘actual entrapment’ was demonstrated when proniosomes were
made with 1:1 CH to surfactant. SEM images showed different surface
morphologies of proniosomes in accordance to using different carriers.
LTZ is crystalline in its pure powder, as shown by both DSC and XRD;
however, it was converted into its amorphous form upon incorporation
into proniosomes. Hydration of lipid with deuterium oxide (D2O) fa-
cilitated the separation of entrapped drug, leading to more reliable
entrapment efficiency determination, which was referred to as ‘actual
entrapment’ which was at highest (approx. 74%) when LTZ was in-
corporated into sucrose-based proniosomes (CH:T80; 1:1). Storage of
niosomes for 3 months provided evidence of drug leakage, slightly
when storage occurred at 4 °C and tremendously when formulation was
stored at RT. The release study showed that niosomes had a biphasic
release profile where the drug was released rapidly during the first 24 h,
so that the total amount of drug released reached approx. 65%, 59%
and 53% for sorbitol-based proniosomes, sucrose-based proniosomes
and conventional niosomes, respectively, whilst the drug in a suspen-
sion formulation had less than 40% of the drug released. After one
week, the drug release was very slow and similar level of release was
exhibited for the three formulations, being approximately 75%, 68%
and 69%, respectively, compared to 51% released from the suspension
formulation. After one month, all four formulations had already re-
leased at least 95% of the drug. The faster release from niosomes
compared to the suspension formulation was attributed to the enhanced
drug dissolution provided by the surfactant. The slightly faster initial
release from proniosome formulations compared to the conventional
niosomes is attributed to a possible interaction between the sugars and
the polar headgroups of the surfactant, affecting membrane packing
and drug release. The release profile from niosomes fits best with the
Higuchi model.
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